What is Walstrum in the medical context?

Waldenström Macroglobulinemia: Definition and Clinical Overview

Waldenström macroglobulinemia (WM) is a rare B-cell lymphoproliferative disorder characterized by bone marrow infiltration with lymphoplasmacytic cells and the production of monoclonal IgM protein in the serum. 1, 2

Core Diagnostic Features

WM is defined by the following essential characteristics:

• Bone marrow involvement: Lymphoplasmacytic infiltration showing small lymphocytes with plasmacytoid/plasma cell differentiation 1, 2
• IgM monoclonal protein: Must be IgM specifically (not IgG or IgA) 2
• Immunophenotype: Cells are typically sIgM+, CD19+, CD20+, CD22+, and usually negative for CD5, CD10, and CD23 (though 10-20% may express these markers) 1
• MYD88 mutation: Present in >90% of cases, particularly the L265P variant, which helps differentiate WM from IgM myeloma or marginal zone lymphoma 1, 3

Clinical Spectrum and Classification

WM exists on a spectrum of disease severity 2:

IgM MGUS (Monoclonal Gammopathy of Undetermined Significance)

• Serum IgM <3 g/dL
• Bone marrow infiltration <10%
• No symptoms, anemia, or organomegaly
• Not considered malignant—only 1.5% annual risk of progression 2

Smoldering (Asymptomatic) WM

• Serum IgM ≥3 g/dL and/or bone marrow infiltration ≥10%
• No end-organ damage or symptoms
• 6% annual risk of progression to symptomatic disease 2

Symptomatic WM

• Requires treatment when patients develop constitutional symptoms, cytopenias, hyperviscosity, neuropathy, organomegaly, or other IgM-related complications 2, 4

Key Clinical Manifestations

Hyperviscosity syndrome is a hallmark complication occurring when IgM levels become markedly elevated, causing:

• Mucosal and skin bleeding
• Visual disturbances with characteristic retinal venous "sausaging" on funduscopy
• Neurologic symptoms 5

Other manifestations include:

• Cytopenias (anemia, thrombocytopenia)
• Peripheral neuropathy
• Lymphadenopathy and splenomegaly
• Cryoglobulinemia 2, 5

Epidemiology

WM is rare, with approximately 1,000-1,500 new cases diagnosed annually in the United States 1. The disease has a highly variable natural history—some patients never require treatment, while others need immediate intervention 2.

Pathophysiology

The genetic landscape of WM includes 3, 6:

• MYD88 mutations (95-97% of cases): Drive BTK, IRAK1/IRAK4, and HCK signaling
• CXCR4 mutations (30-40%): Promote AKT and ERK signaling, associated with higher disease burden and treatment resistance
• Chromosome 6q deletions: Common, affecting genes regulating NF-κB and apoptosis
• ARID1A and CD79B mutations: Less common but clinically relevant

Treatment Indications

Not all patients require immediate treatment. Therapy is indicated for 2, 4:

• Constitutional symptoms (fever, night sweats, weight loss, fatigue)
• Hemoglobin ≤10 g/dL or platelets <100 × 10⁹/L
• Symptomatic hyperviscosity
• Progressive symptomatic lymphadenopathy or splenomegaly
• Symptomatic peripheral neuropathy
• Systemic amyloidosis or renal insufficiency
• Symptomatic cryoglobulinemia

First-Line Treatment Options

Rituximab-based regimens are the preferred initial treatment for most symptomatic patients 7, 4:

• Rituximab monotherapy: Appropriate for low-risk patients with modest hematologic compromise (Level IIa, Grade B) 7, 2
• Combination regimens (Level IIa, Grade B) 7:
  • Bendamustine + rituximab (BR)
  • Cyclophosphamide, dexamethasone, rituximab (DRC)
  • R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab)
  • Nucleoside analogs (fludarabine or cladribine) + rituximab

For hyperviscosity requiring rapid control: Plasmapheresis followed immediately by bortezomib, dexamethasone, and rituximab 7, 4

Important Caveats

• Rituximab flare: Some patients experience paradoxical IgM increase after rituximab, potentially lasting up to 4 months—this does not indicate treatment failure but may require plasmapheresis 2
• Stem cell preservation: Avoid prolonged alkylating agents and nucleoside analogs in transplant candidates 7
• MYD88/CXCR4 mutation status: Affects treatment selection, particularly for BTK inhibitors like ibrutinib 3